Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
ET-743 in Men with Advanced Prostate Cancer
This study is currently recruiting patients.
Sponsored by: | Johnson & Johnson Pharmaceutical Research and Development, L.L.C.
PharmaMar
|
---|---|
Information provided by: | Johnson & Johnson Pharmaceutical Research and Development, L.L.C. |
Purpose
This is a study to test the safety and effectiveness of an investigational chemotherapy agent in men with advanced prostate cancer. After a subject meets all entry criteria and signs informed consent he will be enrolled in the study. Participants will be required to attend regular clinic visits to receive study medication and have their status monitored. They will also be required to have PSA levels measured multiple times throughout the study. A detailed explanation can be provided by the investigator conducting this study.
Condition | Treatment or Intervention | Phase |
---|---|---|
Prostate Cancer |
Drug: ET-743 (YONDELIS) |
Phase II |
MedlinePlus related topics: Prostate Cancer
Study Type: Interventional
Study Design: Treatment
Eligibility
Genders Eligible for Study: Male
Criteria
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |